Pompano Beach, FL, March 25, 2019 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), today provided a corporate update to the Company’s continuing growth strategy.
In January of 2019, BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc., finalized the transition of its operations to the Companies’ Pompano Beach facility and attained its Human Cell and Tissue Establishment Registration. The new location was designed as a sterile manufacturing and research facility for the production of human allograft products and now houses production, while also providing additional capability for expansion.
This expansion initiative is part of a large-scale effort of focusing the direction of the company on the growth of BioStem Life Sciences, starting with the onboarding of experienced and successful sales personnel. In addition, BioStem Life Sciences brought on three supplementary birth tissue recovery agencies, effectively tripling the material sourcing capabilities of the company, and with that, have begun to expand upon our production capabilities – adding processing technicians and reengineering our manufacturing process flows to allow for greater production capability to meet the needs of the increasing sales.
BioStem Technologies Inc. has also completed a marketing vision and branding refresh in a collaboration with BFW Advertising Inc. The company has successfully launched a completely redesigned corporate website (https://www.biostemtechnologies.com/) which displays the newly penned mission statement, “To courageously strive for better.”
About BioStem Life Sciences, Inc.: A company focused on the development of the highest quality placental-based amniotic tissue products for the ophthalmology, orthopedic and wound care markets, whose mission is to create a new paradigm of healthcare, using breakthrough therapies that treat patients who otherwise without effective treatment options.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
Andrew Van Vurst
info@biostemtech.com
(954) 380-8342